Century Therapeutics, Inc. (IPSC) Current Ratio
- Current ratio · latest quarter: Value 8.28×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.28× | Current assets / current liabilities. $124.77M ÷ $15.07M ≈ 8.28× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 124.77M USD | Assets, Current |
| Current obligations | 15.07M USD | Liabilities, Current |
| Cash and equivalents | 49.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.82M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $124.77M | $15.07M | $49.64M | (m) | (m) | (m) | $4.82M | (m) | 8.28× |
| 2026-03-31 | $139.04M | $13.57M | $51.05M | (m) | (m) | (m) | $3.15M | (m) | 10.25× |
| 2025-12-31 | $120.77M | $20.23M | $61.85M | (m) | (m) | (m) | $4.77M | (m) | 5.97× |
| 2025-09-30 | $137.71M | $22.03M | $55.52M | (m) | (m) | (m) | $2.62M | (m) | 6.25× |
| 2025-06-30 | $160.17M | $14.95M | $56.88M | (m) | (m) | (m) | $3.21M | (m) | 10.72× |
| 2025-03-31 | $169.63M | $14.50M | $51.87M | (m) | (m) | (m) | $3.57M | (m) | 11.70× |
| 2024-12-31 | $194.05M | $129.78M | $58.44M | (m) | (m) | (m) | $3.08M | (m) | 1.50× |
| 2024-09-30 | $206.01M | $19.82M | $52.59M | (m) | (m) | (m) | $2.60M | (m) | 10.39× |
| 2024-06-30 | $203.48M | $19.16M | $41.46M | (m) | (m) | (m) | $3.36M | (m) | 10.62× |
| 2024-03-31 | $199.81M | $16.07M | $46.81M | (m) | (m) | (m) | $3.43M | (m) | 12.44× |
| 2023-12-31 | $176.99M | $17.85M | $47.32M | (m) | (m) | (m) | $2.74M | (m) | 9.92× |
| 2023-09-30 | $173.70M | $20.43M | $55.31M | (m) | (m) | (m) | $5.93M | (m) | 8.50× |
| 2023-06-30 | $161.28M | $19.16M | $64.44M | (m) | (m) | (m) | $3.63M | (m) | 8.42× |
| 2023-03-31 | $255.93M | $27.68M | $86.83M | (m) | (m) | (m) | $3.48M | (m) | 9.24× |
| 2022-12-31 | $319.72M | $29.82M | $84.27M | (m) | (m) | (m) | $5.45M | (m) | 10.72× |
| 2022-09-30 | $361.64M | $26.91M | $111.35M | (m) | (m) | (m) | $5.68M | (m) | 13.44× |
| 2022-06-30 | $383.79M | $21.57M | $112.79M | (m) | (m) | (m) | $4.05M | (m) | 17.79× |
| 2022-03-31 | $365.26M | $21.98M | $126.04M | (m) | (m) | (m) | $9.89M | (m) | 16.62× |
| 2021-12-31 | $228.15M | $15.65M | $56.45M | (m) | (m) | (m) | $7.60M | (m) | 14.57× |
| 2021-09-30 | $300.40M | $19.87M | $101.29M | (m) | (m) | (m) | $11.64M | (m) | 15.12× |
| 2021-06-30 | $402.61M | $21.23M | $272.28M | (m) | (m) | (m) | $13.43M | (m) | 18.97× |
| 2020-12-31 | $78.80M | $12.11M | $27.21M | (m) | (m) | (m) | $8.08M | (m) | 6.51× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |